Predictors of pretreatment CA125 at ovarian cancer diagnosis: a pooled analysis in the Ovarian Cancer Association Consortium

Ana Babic; Daniel W Cramer; Linda E Kelemen; Martin Köbel; Helen Steed; Penelope M Webb; Sharon E Johnatty; Anna deFazio; Diether Lambrechts; Marc T Goodman; Florian Heitz; Keitaro Matsuo; Satoyo Hosono; Beth Y Karlan; Allan Jensen; Susanne K Kjær; Ellen L Goode; Tanja Pejovic; Melissa Moffitt; Estrid Høgdall; Claus Høgdall; Iain McNeish; Kathryn L Terry

doi:10.1007/s10552-016-0841-3

Predictors of pretreatment CA₁₂₅ at ovarian cancer diagnosis: a pooled analysis in the Ovarian Cancer Association Consortium

Ana Babic, Daniel W Cramer, Linda E Kelemen, Martin Köbel, Helen Steed, Penelope M Webb, Sharon E Johnatty, Anna deFazio, Diether Lambrechts, Marc T Goodman, Florian Heitz, Keitaro Matsuo, Satoyo Hosono, Beth Y Karlan, Allan Jensen, Susanne K Kjær, Ellen L Goode, Tanja Pejovic, Melissa Moffitt, Estrid HøgdallClaus Høgdall, Iain McNeish, Kathryn L Terry

Department of Clinical Medicine

8 Citations (Scopus)

Abstract

PURPOSE: Cancer antigen 125 (CA125) is a glycoprotein expressed by epithelial cells of several normal tissue types and overexpressed by several epithelial cancers. Serum CA125 levels are mostly used as an aid in the diagnosis of ovarian cancer patients, to monitor response to treatment and detect cancer recurrence. Besides tumor characteristics, CA125 levels are also influenced by several epidemiologic factors, such as age, parity, and oral contraceptive use. Identifying factors that influence CA125 levels in ovarian cancer patients could aid in the interpretation of CA125 values for individuals.

METHODS: We evaluated predictors of pretreatment CA125 in 13 studies participating in the Ovarian Cancer Association Consortium. This analysis included a total of 5,091 women with invasive epithelial ovarian cancer with pretreatment CA125 measurements. We used probit scores to account for variability in CA125 between studies and linear regression to estimate the association between epidemiologic factors and tumor characteristics and pretreatment CA125 levels.

RESULTS: In age-adjusted models, older age, history of pregnancy, history of tubal ligation, family history of breast cancer, and family history of ovarian cancer were associated with higher CA125 levels while endometriosis was associated with lower CA125 levels. After adjusting for tumor-related characteristics (stage, histology, grade), body mass index (BMI) higher than 30 kg/m2was associated with 10% (95% CI 2, 19%) higher CA125 levels, while race (non-white vs. white) was associated with 15% (95% CI 4, 27%) higher CA125 levels.

CONCLUSION: Our results suggest that high BMI and race may influence CA125 levels independent of tumor characteristics. Validation is needed in studies that use a single assay for CA125 measurement and have a diverse study population.

Original language	English
Journal	Cancer Causes & Control
Volume	28
Issue number	5
Pages (from-to)	459-468
ISSN	0957-5243
DOIs	https://doi.org/10.1007/s10552-016-0841-3
Publication status	Published - 1 May 2017

Keywords

Adult
Aged
Biomarkers, Tumor/blood
CA-125 Antigen/blood
Female
Humans
Middle Aged
Neoplasm Recurrence, Local/blood
Ovarian Neoplasms/blood
Parity
Pregnancy
Prognosis

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1007/s10552-016-0841-3

http://europepmc.org/articles/pmc5593071?pdf=renderLicence: Unspecified

Cite this

Babic, A., Cramer, D. W., Kelemen, L. E., Köbel, M., Steed, H., Webb, P. M., Johnatty, S. E., deFazio, A., Lambrechts, D., Goodman, M. T., Heitz, F., Matsuo, K., Hosono, S., Karlan, B. Y., Jensen, A., Kjær, S. K., Goode, E. L., Pejovic, T., Moffitt, M., ... Terry, K. L. (2017). Predictors of pretreatment CA₁₂₅ at ovarian cancer diagnosis: a pooled analysis in the Ovarian Cancer Association Consortium. Cancer Causes & Control, 28(5), 459-468. https://doi.org/10.1007/s10552-016-0841-3

Babic, A, Cramer, DW, Kelemen, LE, Köbel, M, Steed, H, Webb, PM, Johnatty, SE, deFazio, A, Lambrechts, D, Goodman, MT, Heitz, F, Matsuo, K, Hosono, S, Karlan, BY, Jensen, A, Kjær, SK, Goode, EL, Pejovic, T, Moffitt, M, Høgdall, E , Høgdall, C, McNeish, I & Terry, KL 2017, 'Predictors of pretreatment CA₁₂₅ at ovarian cancer diagnosis: a pooled analysis in the Ovarian Cancer Association Consortium', Cancer Causes & Control, vol. 28, no. 5, pp. 459-468. https://doi.org/10.1007/s10552-016-0841-3

@article{01be7e0afccd4ab0b73ca7eb3e1efcd3,

title = "Predictors of pretreatment CA125 at ovarian cancer diagnosis: a pooled analysis in the Ovarian Cancer Association Consortium",

abstract = "PURPOSE: Cancer antigen 125 (CA125) is a glycoprotein expressed by epithelial cells of several normal tissue types and overexpressed by several epithelial cancers. Serum CA125 levels are mostly used as an aid in the diagnosis of ovarian cancer patients, to monitor response to treatment and detect cancer recurrence. Besides tumor characteristics, CA125 levels are also influenced by several epidemiologic factors, such as age, parity, and oral contraceptive use. Identifying factors that influence CA125 levels in ovarian cancer patients could aid in the interpretation of CA125 values for individuals.METHODS: We evaluated predictors of pretreatment CA125 in 13 studies participating in the Ovarian Cancer Association Consortium. This analysis included a total of 5,091 women with invasive epithelial ovarian cancer with pretreatment CA125 measurements. We used probit scores to account for variability in CA125 between studies and linear regression to estimate the association between epidemiologic factors and tumor characteristics and pretreatment CA125 levels.RESULTS: In age-adjusted models, older age, history of pregnancy, history of tubal ligation, family history of breast cancer, and family history of ovarian cancer were associated with higher CA125 levels while endometriosis was associated with lower CA125 levels. After adjusting for tumor-related characteristics (stage, histology, grade), body mass index (BMI) higher than 30 kg/m2was associated with 10% (95% CI 2, 19%) higher CA125 levels, while race (non-white vs. white) was associated with 15% (95% CI 4, 27%) higher CA125 levels.CONCLUSION: Our results suggest that high BMI and race may influence CA125 levels independent of tumor characteristics. Validation is needed in studies that use a single assay for CA125 measurement and have a diverse study population.",

keywords = "Adult, Aged, Biomarkers, Tumor/blood, CA-125 Antigen/blood, Female, Humans, Middle Aged, Neoplasm Recurrence, Local/blood, Ovarian Neoplasms/blood, Parity, Pregnancy, Prognosis",

author = "Ana Babic and Cramer, {Daniel W} and Kelemen, {Linda E} and Martin K{\"o}bel and Helen Steed and Webb, {Penelope M} and Johnatty, {Sharon E} and Anna deFazio and Diether Lambrechts and Goodman, {Marc T} and Florian Heitz and Keitaro Matsuo and Satoyo Hosono and Karlan, {Beth Y} and Allan Jensen and Kj{\ae}r, {Susanne K} and Goode, {Ellen L} and Tanja Pejovic and Melissa Moffitt and Estrid H{\o}gdall and Claus H{\o}gdall and Iain McNeish and Terry, {Kathryn L}",

year = "2017",

month = may,

day = "1",

doi = "10.1007/s10552-016-0841-3",

language = "English",

volume = "28",

pages = "459--468",

journal = "Cancer Causes & Control",

issn = "0957-5243",

publisher = "Springer",

number = "5",

}

TY - JOUR

T1 - Predictors of pretreatment CA125 at ovarian cancer diagnosis

T2 - a pooled analysis in the Ovarian Cancer Association Consortium

AU - Babic, Ana

AU - Cramer, Daniel W

AU - Kelemen, Linda E

AU - Köbel, Martin

AU - Steed, Helen

AU - Webb, Penelope M

AU - Johnatty, Sharon E

AU - deFazio, Anna

AU - Lambrechts, Diether

AU - Goodman, Marc T

AU - Heitz, Florian

AU - Matsuo, Keitaro

AU - Hosono, Satoyo

AU - Karlan, Beth Y

AU - Jensen, Allan

AU - Kjær, Susanne K

AU - Goode, Ellen L

AU - Pejovic, Tanja

AU - Moffitt, Melissa

AU - Høgdall, Estrid

AU - Høgdall, Claus

AU - McNeish, Iain

AU - Terry, Kathryn L

PY - 2017/5/1

Y1 - 2017/5/1

N2 - PURPOSE: Cancer antigen 125 (CA125) is a glycoprotein expressed by epithelial cells of several normal tissue types and overexpressed by several epithelial cancers. Serum CA125 levels are mostly used as an aid in the diagnosis of ovarian cancer patients, to monitor response to treatment and detect cancer recurrence. Besides tumor characteristics, CA125 levels are also influenced by several epidemiologic factors, such as age, parity, and oral contraceptive use. Identifying factors that influence CA125 levels in ovarian cancer patients could aid in the interpretation of CA125 values for individuals.METHODS: We evaluated predictors of pretreatment CA125 in 13 studies participating in the Ovarian Cancer Association Consortium. This analysis included a total of 5,091 women with invasive epithelial ovarian cancer with pretreatment CA125 measurements. We used probit scores to account for variability in CA125 between studies and linear regression to estimate the association between epidemiologic factors and tumor characteristics and pretreatment CA125 levels.RESULTS: In age-adjusted models, older age, history of pregnancy, history of tubal ligation, family history of breast cancer, and family history of ovarian cancer were associated with higher CA125 levels while endometriosis was associated with lower CA125 levels. After adjusting for tumor-related characteristics (stage, histology, grade), body mass index (BMI) higher than 30 kg/m2was associated with 10% (95% CI 2, 19%) higher CA125 levels, while race (non-white vs. white) was associated with 15% (95% CI 4, 27%) higher CA125 levels.CONCLUSION: Our results suggest that high BMI and race may influence CA125 levels independent of tumor characteristics. Validation is needed in studies that use a single assay for CA125 measurement and have a diverse study population.

AB - PURPOSE: Cancer antigen 125 (CA125) is a glycoprotein expressed by epithelial cells of several normal tissue types and overexpressed by several epithelial cancers. Serum CA125 levels are mostly used as an aid in the diagnosis of ovarian cancer patients, to monitor response to treatment and detect cancer recurrence. Besides tumor characteristics, CA125 levels are also influenced by several epidemiologic factors, such as age, parity, and oral contraceptive use. Identifying factors that influence CA125 levels in ovarian cancer patients could aid in the interpretation of CA125 values for individuals.METHODS: We evaluated predictors of pretreatment CA125 in 13 studies participating in the Ovarian Cancer Association Consortium. This analysis included a total of 5,091 women with invasive epithelial ovarian cancer with pretreatment CA125 measurements. We used probit scores to account for variability in CA125 between studies and linear regression to estimate the association between epidemiologic factors and tumor characteristics and pretreatment CA125 levels.RESULTS: In age-adjusted models, older age, history of pregnancy, history of tubal ligation, family history of breast cancer, and family history of ovarian cancer were associated with higher CA125 levels while endometriosis was associated with lower CA125 levels. After adjusting for tumor-related characteristics (stage, histology, grade), body mass index (BMI) higher than 30 kg/m2was associated with 10% (95% CI 2, 19%) higher CA125 levels, while race (non-white vs. white) was associated with 15% (95% CI 4, 27%) higher CA125 levels.CONCLUSION: Our results suggest that high BMI and race may influence CA125 levels independent of tumor characteristics. Validation is needed in studies that use a single assay for CA125 measurement and have a diverse study population.

KW - Adult

KW - Aged

KW - Biomarkers, Tumor/blood

KW - CA-125 Antigen/blood

KW - Female

KW - Humans

KW - Middle Aged

KW - Neoplasm Recurrence, Local/blood

KW - Ovarian Neoplasms/blood

KW - Parity

KW - Pregnancy

KW - Prognosis

U2 - 10.1007/s10552-016-0841-3

DO - 10.1007/s10552-016-0841-3

M3 - Journal article

C2 - 28050675

SN - 0957-5243

VL - 28

SP - 459

EP - 468

JO - Cancer Causes & Control

JF - Cancer Causes & Control

IS - 5

ER -